Company Filing History:
2 out of 168 
2 out of 8 
2 out of 64 
Years Active: 2016-2017
Title: Inventor Spotlight: Franz-Ferdinand Roch
Introduction
Franz-Ferdinand Roch is an innovative inventor based in Vienna, Austria, known for his contributions to the field of pharmaceutical sciences. With a total of two patents to his name, he has focused his research on providing novel therapeutic solutions for viral diseases.
Latest Patents
Roch's latest patents include the invention related to "Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease." This invention details a compound characterized by the general formula (V), which may exist in various forms, such as pharmaceutically acceptable salts, solvates, polymorphs, codrugs, cocrystals, prodrugs, tautomers, racemates, enantiomers, or diastereomers. The significant aspect of this invention is its potential application in treating, ameliorating, or preventing viral diseases, along with the provision of specific combination therapies.
Career Highlights
Throughout his career, Franz-Ferdinand Roch has worked with notable companies in the pharmaceutical industry, including F. Hoffmann-La Roche AG and Savira Pharmaceuticals GmbH. His experience in these organizations has allowed him to advance his research and contribute to impactful innovations in medicine.
Collaborations
In his professional journey, Roch has collaborated with talented individuals, including Tanja Schulz-Gasch and Robert James Weikert. These partnerships have further enriched his work and provided a collaborative environment conducive to innovation and enhancement in therapeutic research.
Conclusion
Franz-Ferdinand Roch exemplifies the spirit of innovation through his dedicated work and patented inventions. His contributions to the pharmaceutical field, particularly concerning viral diseases, underscore the importance of research and collaboration in driving advancements in medical treatment. As he continues to develop new compounds and therapies, the impact of his work is poised to grow, offering hope to many affected by viral conditions.